Center for Biotechnology and Genomic Medicine25
The Center for Biotechnology and Genomic Medicine's (CBGM) research efforts focus on two main areas: 1) discovery and validation of biomarkers for disease prediction and diagnosis, 2) pharmacomics and drug discovery for personalized medicine. CBGM is home of four internationally renowned programs in diabetes research: The Environmental Determinants of Diabetes in the Young (TEDDY), the Prospective Assessment in Newborns of Diabetes Autoimmunity (PANDA), the Diabetic Complications Consortium (DCC) and the Mouse Metabolic Phenotype Consortium (MMPC). Additional research programs include autoimmune diseases, transplantation, and cancer. These research programs are supported by an annual extramural funding of approximately $12 million.
Latest publications
- A novel subnetwork based analysis reveals shared pathways in T-cell mediated autoimmunity19Apr2016
- The Autoimmune Regulator (Aire) Confers Immunosuppressive Properties to Dendritic Cells23Feb2015
- Large Scale Gene Expression Analysis Reveals Insight into Pathways Related to Type 1 Diabetes and Associated Complications12Feb2015
- Lack of an association of miR-938 SNP in IDDM10 with human type 1 diabetes26Oct2012
- Reduced Serum Vitamin Dâ Binding Protein Levels Are Associated With Type 1 Diabetes26Oct2012
All items in the repository are protected by copyright; they may be used for educational purposes with proper attribution. All other uses require the author's permission.